AstraZeneca considers merger with Bristol Myers Squibb
Story essentials
AstraZeneca, Bristol Myers Squibb
UK, USA
August 2, 2026
This page is produced by collecting and structuring multiple public reports. Sections based only on reporting or testimony affect the displayed assessment, and the page is updated when new information is identified.
About this article
COMPAMIR Editorial Team
The COMPAMIR editorial team brings together public reporting and links to the original coverage. We update the page as new information emerges.
Read our editorial policy- Earlier version 18/2/2026, 10:50:35 PM
AstraZeneca is reportedly in talks to merge with US rival Bristol Myers Squibb. The combined market value of the two companies is approximately 400 billion dollars. A deal could create one of the world's largest pharmaceutical companies.
Read next
Prioritized by shared people, places, and events.
US Federal Reserve interest rate policy debate
St Louis Fed president Alberto Musalem advocated for a quarter-percentage-point interest rate increase. Three FOMC members dissented against the decision to leave rates unchanged. Traders are betting on a potential rate hike in September.